| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 33,890 | 34,030 | 13.01. | |
| 33,845 | 34,190 | 13.01. |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 600,00 | 4 | |||
| 516,00 | 7 | |||
| 414,40 | 40 | |||
| 170,00 | 8 | |||
| 150,00 | 557 | |||
| 35,000 | 200 | |||
| 34,170 | 267 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/0qf.htm [/URL] | ||||
| 267 | 33,825 | |||
| 50 | 27,000 | |||
| 700 | 24,120 | |||
| 120 | 20,800 | |||
| 300 | 20,000 | |||
| 100 | 19,900 | |||
| 1.052 | 0,000 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 2.589 | 0,418 | 1.083 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 17:35:38 | 32,560 | 59 |
| 17:25:47 | 32,700 | 25 |
| 17:25:47 | 32,700 | 125 |
| 17:25:17 | 32,590 | 232 |
| 17:24:49 | 32,580 | 7 |
| 17:24:48 | 32,560 | 250 |
| 17:24:26 | 32,580 | 125 |
| 17:19:31 | 32,500 | 7 |
| 17:19:28 | 32,500 | 3 |
| 17:18:57 | 32,395 | 6 |
| 17:16:01 | 32,580 | 153 |
| 17:15:57 | 32,600 | 20 |
| 17:15:57 | 32,600 | 23 |
| 17:15:57 | 32,600 | 125 |
| 17:15:06 | 32,515 | 55 |
| 17:15:06 | 32,515 | 125 |
| 17:11:14 | 32,330 | 1 |
| 17:10:20 | 32,355 | 113 |
| 17:08:57 | 32,350 | 1 |
| 17:08:52 | 32,240 | 7 |
| Tagesumsatz Xetra | +3,610 +12,47 % | 32.524 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | RBC Capital maintains Moderna stock rating, cites 2026 catalysts | 105 | Investing.com | ||
| Mo | Moderna Raises 2025 Forecast, Targets Major Vaccine And Cancer Readouts In 2026 | 529 | AFX News | WASHINGTON (dpa-AFX) - Moderna (MRNA) heads into 2026 with stronger finances and a crowded late-stage pipeline after an aggressive cost reset in 2025 and a slate of regulatory and clinical milestones... ► Artikel lesen | |
| MODERNA Aktie jetzt für 0€ handeln | |||||
| Mo | Opening Bell: Wall Street zum Wochenstart schwächer; American Express, Moderna, Alibaba, Oklo, ... | 630 | Der Aktionär | Die US-Börsen steuern am Montag in Rekordnähe auf einen schwächeren Handelsauftakt zu. Seine Spuren hinterlässt der Streit zwischen US-Präsident Donald Trump und dem Fed-Chef Jerome Powell, der sich... ► Artikel lesen | |
| Mo | Opening Bell: American Express, Oklo, Vistra Energy, Alibaba, Xpeng, Tempus AI, Moderna | 546 | Der Aktionär TV | Die Wall Street hat sich am Freitag mit guter Stimmung ins Wochenende verabschiedet. Alle großen Indizes legten zu. Der S&P 500 verzeichnete sogar ein neues Rekordhoch. Heute droht allerdings ein Fehlstart.... ► Artikel lesen | |
| Mo | Moderna reiterates target of up to 10% revenue growth in 2026 | 32 | Seeking Alpha |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| Di | Illumina, Inc.: Illumina Announces Preliminary Unaudited Financial Results for Fourth Quarter and Fiscal Year 2025 | PR Newswire | SAN DIEGO, Jan. 13, 2026 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today announced unaudited preliminary financial results for... ► Artikel lesen | |
| Di | Fortress Biotech, Inc.: Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States | GlobeNewswire (Europe) | Rare Pediatric Disease Priority Review Voucher (PRV) granted by FDA at approval to be transferred from Sentynl Therapeutics to Cyprium Cyprium eligible to receive tiered royalties and up to $129 million... ► Artikel lesen | |
| Di | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 13.01.2026 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 13.01.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 13.01.2026ISIN NameCA78471G1000 SOL... ► Artikel lesen | |
| Di | Edgewise Therapeutics Provides Corporate Updates and Highlights Priorities for 2026 | PR Newswire | - Advancing robust clinical pipeline of novel therapeutics for muscular dystrophies and serious cardiac conditions -
- Presenting at the 44th Annual J.P. Morgan... ► Artikel lesen | |
| Di | CYTOMED THERAPEUTICS LIMITED: CytoMed Therapeutics' new year update and seeks shareholders' feedback on proposal to improve shareholder value for their patient capital | GlobeNewswire (Europe) | SINGAPORE, Jan. 13, 2026 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or the "Company"), a Singapore-based clinical stage biopharmaceutical company focused on harnessing... ► Artikel lesen |